Core Insights - Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) is recognized as one of the best-performing pharmaceutical stocks in 2025, with a focus on developing AMX0318 for post-bariatric hypoglycemia and other rare diseases [1] - The company has demonstrated strong confidence in the therapeutic potential of AMX0318, a long-acting GLP-1 receptor antagonist, which has shown robust preclinical and chemical properties [2] - Amylyx anticipates advancing AMX0318 into investigational new drug (IND)-enabling studies later this year, with an IND targeted for 2027 [3] Group 1 - AMX0318 was selected as a development candidate through a collaboration with Gubra A/S, which specializes in peptide-based drug discovery [1] - The management of Amylyx Pharmaceuticals is optimistic about the long-acting administration potential of AMX0318, supported by significant data from their first-in-class GLP-1 receptor antagonist, avexitide [2] - The pivotal Phase 3 LUCIDITY trial for avexitide is expected to complete recruitment by Q1 2026, with topline data anticipated in Q3 2026 [2] Group 2 - The company provides therapies for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), with its commercial product being Relyvrio, also known as Albrioza in Canada [3] - AMX0318 has completed extensive preclinical evaluation, positioning the company for future advancements in its drug development pipeline [3]